Woburn, Massachusetts | April 10, 2026
Replimune Group Inc. has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) seeking approval of RP1 in combination with nivolumab for the treatment of advanced melanoma. The decision represents a significant regulatory setback for the company’s lead oncolytic immunotherapy, despite prior breakthrough therapy designation and promising clinical data. The CRL indicates that the FDA requires additional information before the application can be approved, raising concerns about regulatory alignment and delaying potential patient access to this innovative cancer therapy.
Regulatory Disagreement Highlights Clinical and Review Challenges
The CRL has brought to light a notable disagreement between Replimune and the FDA regarding the adequacy of clinical evidence supporting RP1’s efficacy. The company emphasized that data from the IGNYTE trial demonstrated a 34% response rate with a median duration of response of 24.8 months, alongside a favorable safety profile, in patients who had progressed on prior anti-PD-1 therapies.
Despite these results, the FDA determined that the submitted dataset was insufficient for approval, reflecting a stricter interpretation of regulatory requirements. Replimune also pointed to inconsistent communication and changes in the FDA review team, which may have contributed to differing expectations during the review process. This situation underscores the complexities of accelerated approval pathways and the importance of clear regulatory alignment throughout drug development.
Impact on Innovation and Oncology Drug Development
Advertisement
The FDA’s decision has broader implications for the biopharmaceutical industry, particularly in the development of novel immunotherapies. RP1 is based on a genetically engineered herpes simplex virus (HSV-1) designed to enhance tumor cell killing and systemic immune activation, representing a cutting-edge approach in cancer treatment. The setback raises concerns about the predictability of regulatory pathways, especially for therapies granted breakthrough designation. Replimune has warned that without timely accelerated approval, the continued development of RP1 may not be viable, leading to operational restructuring and job reductions, including scaling back U.S.-based manufacturing. This highlights the delicate balance between regulatory rigor and fostering innovation, particularly in areas of high unmet medical need such as advanced melanoma.
Future Outlook for RP1 and Melanoma Treatment Landscape
Advanced melanoma remains one of the most aggressive forms of skin cancer, with approximately 112,000 new cases expected in the U.S. in 2026 and nearly 8,500 annual deaths, emphasizing the urgent need for new therapies. RP1, developed using Replimune’s proprietary RPx platform, aims to deliver localized tumor destruction and systemic immune response activation, potentially improving outcomes when combined with immune checkpoint inhibitors like nivolumab. While the CRL delays its progress, the company may pursue additional data generation or regulatory engagement to address the FDA’s concerns. The outcome of this process will be closely watched by stakeholders, as it could influence future approval strategies for oncolytic virus therapies and shape the evolving landscape of immuno-oncology treatments.
The FDA’s issuance of a Complete Response Letter to Replimune Group Inc. marks a critical moment in the development of RP1 for advanced melanoma, highlighting both the promise and challenges of next-generation cancer immunotherapies. While the therapy has demonstrated encouraging clinical results, regulatory hurdles remain a significant barrier to market entry. The decision underscores the need for continued collaboration between industry and regulators to ensure that innovative treatments reach patients efficiently while maintaining high standards of safety and efficacy.
Source: Replimune press release
